HC Wainwright Forecasts Annexon's Q3 Earnings (NASDAQ:ANNX)

Key Points

• HC Wainwright lowered Annexon’s Q3 2026 EPS forecast to a loss of $0.28 from $0.27, while maintaining a Buy rating and $14 price target.
• The analyst expects continued losses through 2028 but forecasts a shift to profitability in 2029, with projected EPS of $0.58 in FY2029 and $1.36 in FY2030.
• Annexon shares opened at $3.83, below their 50-day and 200-day moving averages, and the company’s latest quarterly loss of $0.28 per share missed the $0.24 consensus estimate.

Annexon, Inc. (NASDAQ:ANNX - Free Report) - Analysts at HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for shares of Annexon in a report released on Monday, October 19th. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings per share of ($0.28) for the quarter, down from their previous forecast of ($0.27). HC Wainwright currently has a "Buy" rating and a $14.00 price objective on the stock. The consensus estimate for Annexon's current full-year earnings is ($1.05) per share. HC Wainwright also issued estimates for Annexon's Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.03) EPS, Q1 2027 earnings at ($0.20) EPS, Q2 2027 earnings at ($0.20) EPS, Q3 2027 earnings at ($0.20) EPS, Q4 2027 earnings at ($0.10) EPS, FY2027 earnings at ($0.69) EPS, FY2028 earnings at ($0.16) EPS, FY2029 earnings at $0.58 EPS and FY2030 earnings at $1.36 EPS.

ANNX has been the subject of several other reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of Annexon in a research report on Monday, July 13th. JPMorgan Chase & Co. raised their price objective on shares of Annexon from $14.00 to $15.00 and gave the company an "overweight" rating in a research report on Wednesday, September 30th. Citigroup initiated coverage on shares of Annexon in a research report on Tuesday, July 21st. They set a "market underperform" rating on the stock. Needham & Company LLC lifted their price objective on shares of Annexon from $11.00 to $25.00 and gave the stock a "buy" rating in a report on Wednesday, July 15th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Annexon in a research report on Thursday, October 15th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $15.29.

Annexon Stock Performance

ANNX stock opened at $3.83 on Wednesday. The company's 50 day moving average is $4.42 and its 200 day moving average is $5.13. Annexon has a 1-year low of $2.54 and a 1-year high of $7.18.

Annexon (NASDAQ:ANNX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04).

Institutional Trading of Annexon

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of Annexon during the second quarter valued at about $77,312,000. Redmile Group LLC increased its holdings in shares of Annexon by 44.8% in the first quarter. Redmile Group LLC now owns 14,549,768 shares of the company's stock worth $80,606,000 after buying an additional 4,499,124 shares during the period. Siren L.L.C. purchased a new position in shares of Annexon in the first quarter worth about $21,931,000. Palo Alto Investors LP bought a new stake in shares of Annexon in the 2nd quarter valued at about $16,833,594. Finally, Bank of America Corp DE lifted its stake in shares of Annexon by 165.3% in the 1st quarter. Bank of America Corp DE now owns 4,259,995 shares of the company's stock valued at $23,600,000 after acquiring an additional 2,654,414 shares during the last quarter.

Insider Activity at Annexon

In other news, CEO Douglas Love acquired 26,065 shares of the firm's stock in a transaction that occurred on Thursday, September 24th. The shares were bought at an average cost of $3.83 per share, with a total value of $99,828.95. Following the acquisition, the chief executive officer owned 390,476 shares in the company, valued at approximately $1,495,523.08. This represents a 7.15% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 10.31% of the company's stock.

Annexon News Roundup

Here are the key news stories impacting Annexon this week:

• Positive Sentiment: HC Wainwright raised its FY2027 EPS forecast to a loss of $0.69 from $0.74, FY2028 to a loss of $0.16 from $0.39, FY2029 to $0.58 from $0.03, and FY2030 to $1.36 from $0.45. The revisions imply a faster long-term path toward profitability, with positive EPS now projected beginning in FY2029.
• Positive Sentiment: The firm reiterated its Buy rating and $14 price objective, signaling substantial potential upside if Annexon’s pipeline and commercialization plans support the projected long-term earnings growth.
• Neutral Sentiment: HC Wainwright expects quarterly losses of approximately $0.20 per share throughout FY2027, followed by a $0.10 loss in the fourth quarter. Annexon is therefore still expected to remain unprofitable over the next several quarters.
• Negative Sentiment: HC Wainwright cut its Q3 2026 EPS estimate to a loss of $0.28 from $0.27, Q4 2026 to a loss of $0.24 from $0.22, and FY2026 to a loss of $1.03 from $0.99. These reductions point to somewhat weaker near-term financial expectations.
• Negative Sentiment: The company’s latest reported quarterly loss also missed consensus expectations, and shares remain below their 50-day and 200-day moving averages. Investors may remain cautious until Annexon demonstrates improved execution or provides stronger clinical and commercial updates. Annexon stock information

About Annexon

Annexon, Inc is a clinical-stage biopharmaceutical company developing therapies for diseases driven by activation of the classical complement pathway, an immune-system mechanism involved in inflammation and tissue damage. The company's approach is designed to selectively inhibit complement activity while preserving other parts of the immune response.

Annexon's pipeline has included ANX005, an investigational monoclonal antibody that targets C1q, an initiating protein in the classical complement pathway.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.